Bliss GVS Pharma Limited
BLISSGVS.NS
Get informed when a big investor buys or sells
+ FollowMarket Cap$69.57B
Close$
$84.38
87.1% downside
Current Fair Value
87.1% downsideOvervalued by 87.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $69.57 Billion |
|---|---|
| Enterprise Value | $69.57 Billion |
| Dividend Yield | $1.50 (0.23%) |
| Earnings per Share | $12.23 |
| Beta | 1.13 |
| Outstanding Shares | 105,914,164 |
Return
| Return on Equity | 11.06% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | 51.33 |
|---|---|
| PEG | 312.91 |
| Price to Sales | 6.98 |
| Price to Book Ratio | 5.65 |
| Enterprise Value to Revenue | 6.92 |
| Enterprise Value to EBIT | 34.88 |
| Enterprise Value to Net Income | 51 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Bliss GVS Pharma Limited
1,033 employees
CEO: Shibroor Narsimha Kamath Bliss GVS Pharma Limited, founded in 1984 and based in Mumbai, India, operates as a pharmaceutical enterprise focused on the development, production, and commercialization of a vast array of medicinal formulations and general healthcare ...